Ignite Creation Date:
2025-12-24 @ 11:57 PM
Ignite Modification Date:
2026-02-20 @ 2:22 AM
Study NCT ID:
NCT00910858
Status:
COMPLETED
Last Update Posted:
2013-09-30
First Post:
2009-05-28
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
Sponsor:
Celgene Corporation
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CC-5013-PK-002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None